Note : Patients may be seen more fre quently as clinically indicated. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 20At each scheduled follow-up eva luation, patients will undergo: xPhysical examination, including ECOG xVital signs xCBC w/differential xAcute Care Panel (sodium, pota ssium, chloride, bicarbonate, cre atinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Cre atinine Kinase, Lactate Dehydrogenase, Total Protein xLymphocyte phenotyping (TBNK) xȕ-HCG pregnancy test (serum or urine) on all females of child-bear ing potential (complete at all follow-up evalu ations within 4 months after th e last vaccine) xToxicity assessment, including a review of systems xResearch samples as described in Section 5 xImaging studies as performed at baseline to determine tumor res ponse. If clinically indicated, other scans or x-rays may be performed, e.g., brain M RI, bone scan.